CWBR - CohBar collaborates with NIAID for CB5064 analogs in COVID-19-related ARDS

CohBar ([[CWBR]] -2.2%) has signed a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases ((NIAID)) to evaluate the potential of CB5064 Analogs for the treatment of COVID-19 associated Acute Respiratory Distress Syndrome ((ARDS)).The program has shown positive results in preclinical studies.The NIAID will be responsible for any study conducted under the agreement, wherein NIAID will be provided with CohBar's CB5064 Analogs to test in preclinical models of COVID-19.

For further details see:

CohBar collaborates with NIAID for CB5064 analogs in COVID-19-related ARDS